FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 16:01 ET
|
FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
Global Interstitial Lung Disease Market to Surpass US$ 2453.5 Million by 2028, Says Coherent Market Insights (CMI)
December 27, 2021 08:30 ET
|
CMI
SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected...
FibroGen to Present at Upcoming Investor Conferences
November 02, 2021 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following...
Global Idiopathic Pulmonary Fibrosis Disease Treatment Markets, 2018-2019 & 2020-2024
September 08, 2021 03:58 ET
|
Research and Markets
Dublin, Sept. 08, 2021 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets" report has been added to ResearchAndMarkets.com's offering.The current report...
Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space
August 17, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space The Idiopathic Pulmonary...
Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Report 2021 with 10-Year Disease Incidence and Prevalence Forecasts
July 13, 2021 05:13 ET
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
May 11, 2021 07:01 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
March 25, 2021 16:05 ET
|
Trevi Therapeutics
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW...
Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
August 25, 2020 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...